Cruz-Contreras DG

Language: Spanish
References: 16
Page: 262-267
PDF size: 418.99 Kb.

ABSTRACT

Invasive aspergillosis remains as one of the most important causes of morbidity and mortality in allogeneic stem cell transplantation (alloSCT) recipient patients. The risk of acquiring this kind of invasive fungal infection depends on multiple factors, prolonged neutropenia and immunosuppression are the most important of them. Invasive aspergillosis is characterized by any organ or tissue invasion, lungs are the most often affected (pulmonary aspergillosis). The incidence of invasive aspergillosis has decreased in the last years due to routine inclusion of diagnosis tests and prophylactic drugs in transplant protocols in worldwide hospitals. Despite the above, invasive aspergillosis has an elevated mortality among patients, this is the reason why it is important to do a soon diagnosis and thus start aggressive antifungal treatment.

REFERENCES

1. Blyth C, Gilroy N, et al. Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haematopoyetic stem cell transplantation, 2014. Int Med J 2004;44:1333-1349.

2. Mikulska M, Raiola A, et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis od 306 patients. Bone Marrow Transplantation 2009;44:361-370.

3. Marr K, Carter R, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2012;100:4358-4366.

4. Marchetti O, Lamoth F, et al. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal disease in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplantation 2012;47:846-854.

5. Upton A, Kirby K, et al. Invasive aspergillosis following hematopoietic stem cell transplantation: Outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007;44:531-540.

6. Kontoyiannis D, Marr K, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplants recipients, 2001-2006: Overview of the Transplant- Associated Infections Surveillance Network (TRANSNET) database. CID 2010;50:1091-1100.

7. Yuquian Sun, Meng F, et al. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: A multicenter prospective observational study. Biol Blood Marrow Transplant 2015;21:1117-1126.

8. Arellano-Galindo J, Moreno-Galvan M, Sarti E. Infecciones por hongos y neutropenia en un Hospital pediátrico de tercer nivel. Salud Pública Méx 2008;50:197-199.

9. Pauw B, Walsh T, et al. Revised definition of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Disease Mycosis Study Group (EORCT/MGS) Consensus Group. Clin Infect Dis 2008;46:1813-1821.

10. Pfeiffer C, Fine J, et al. Diagnosis of invasive aspergillosis using a galactomannan assay: A meta-analysis. Clin Infect Dis 2006;42:1417-1427.

11. Vázquez L. Antifungal prophylaxis in immunocompromised patients. Mediterr J Hematol Infect Dis 2016;8:1-9.

12. Marks D, Pagliuca A, et al. Voriconazol versus itraconazol for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol 2011;155:318-327.

13. Cornely O, Maertens J, et al. Posaconazol vs fluconazol or itraconazol prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-359.

14. Herbrecht R, Denning D, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415.

15. Cornely O, Maertens J, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad Trial). Clin Infect Dis 2007;44:1289-1297.

16. Herbrecht R, Maertens J. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer Study. Bone Marrow Transplantation 2010;45:1227-1233.